Ubiquitous background standard-of-care therapies neutralize the observable clinical efficacy of next-generation drug candidates.
The widespread real-world use of established standard-of-care treatments creates a high clinical baseline that masks the incremental benefits of next-generation therapies in late-stage combination trials.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The heavy baseline and mid-trial utilization of standard-of-care stabilizers in both arms neutralized the observable clinical benefit of the next-generation therapy.
The clinical efficacy of the next-generation gene silencer was completely neutralized when layered on top of existing standard-of-care stabilizer treatments.
The clinical benefit of the next-generation silencer was completely neutralized when layered on top of existing standard-of-care stabilizer treatments.
The high prevalence of standard-of-care stabilizer use in the study population neutralized any observable benefit of adding the next-generation gene silencer.
The high potency of the standard-of-care backbone therapy blunted the next-generation candidate's ability to demonstrate a statistically significant benefit.